Testimonial by Mathieu Nadeau-Vallée!

Mathieu Nadeau-Vallée

Contributed Article: “Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists

TESTIMONIAL BY Guido Rubboli!

Guido Rubboli

Contributed Article: “Management of Antiepileptic Treatment After Epilepsy Surgery – Practices And Problems

 

MOST ACCESSED ARTICLE – Targeted Nanoparticles for the Treatment of Alzheimer’s Disease – Current Pharmaceutical Design

Journal: Current Pharmaceutical Design

Author(s): Rafael Martín-Rapun, Laura De Matteis, Alfredo Ambrosone, Sonia Garcia-Embid, Lucia Gutierrez, Jesus M. de la Fuente

Abstract:

Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.

Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed.

Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration.
Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.

To access the article, please visit: http://www.eurekaselect.com/148709

Highlighted Article – Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies – Current Pharmaceutical Design

cpd- Articles_23-46-Edoardo Ferlazzo

To access this article, please visit: http://www.eurekaselect.com/154784

Testimonial by Liliya Vasileva!

Liliya Vasileva.jpg

Contributed Article: “Current And Emerging Strategies in Osteoporosis Management

Testimonial by Yu-Long Lan!

Yu-Long Lan

Contributed Article: “Aquaporin 4 in Astrocytes Is A Target For Therapy In Alzheimer’s Disease

Podcast: Targeting Human Astrocytes’ Calcium-sensing Receptors for Treatment of Alzheimer’s Disease

Author(s): Ikuko Miyazaki, Masato Asanuma.

For article details, visit: http://www.eurekaselect.com/154088

Subscribe our YouTube channelhttp://bit.ly/1lr0czy

Highlighted Article – Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson’s Disease – Current Pharmaceutical Design

CPD-Articles_23-46-Ikuko Miyazaki

To access this article, please visit: http://www.eurekaselect.com/154088

New Issue :: Current Pharmaceutical Design 23, Issue 8

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

cpd-14-16

Articles from the journal Current Pharmaceutical Design 23, Issue 8:

For details on the articles, please visit this link :: http://bit.ly/2uTs79b

 

 

 

 

 

New Issue :: Current Pharmaceutical Design 23, Issue 7

Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.

Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

cpd-14-16

Articles from the journal Current Pharmaceutical Design 23, Issue 7:

                       For details on the articles, please visit this link :: http://bit.ly/2vaJiWu